Hiroyuki Kamei

Dr. Hiroyuki Kamei


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

26 April 2021 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
TFTomoo Fujii
Tomoo Fujii
MHManako Hanya
Manako Hanya
KMKenta Murotani
Kenta Murotani
HKHiroyuki Kamei
Hiroyuki Kamei
Background: Stigma associated with mental disorders is rooted among many pharmacists, and represents a major barrier to patient support in community-based psychiatry. We developed an assessment scale that is specifically designed to assess the level of stigma that pharmacists may have toward schizophrenia, and then examined the effects of reducing stigma with an educational program that focuses on communication with patients diagnosed with schizophrenia (PDS) using the newly developed Stigma Scale towards Schizophrenia for Community Pharmacists (SSCP). Methods: SSCP was developed by exploratory factor analysis with promax rotation based on responses from 822 randomly selected community pharmacists. Furthermore, a randomized controlled trial was conducted for 115 community pharmacists to clarify the effects of reducing the stigma of schizophrenia using an educational program for them with a focus on communication with PDS. Participants were individually allocated to two groups: educational lecture group (56; only attending a lecture on schizophrenia) or contact-based intervention group (59; communicating with PDS and attending the lecture). The stigma assessment using SSCP was conducted immediately before and after the educational intervention. Results: A total of 4 factors and 27 items were extracted from the exploratory factor analysis to comprise the SSCP. Cronbach’s α of SSCP, social distance at professional pharmacy service (factor I), attitudes towards PDS (factor II), self-disclosure (factor III), and social distance in personal (factor IV) were 0.89, 0.88, 0.76, 0.62, and 0.62, respectively. Educational program-related changes of the median (interquartile range) total SSCP score from baseline were − 9.0 (− 16.0 – − 5.0) in the contact-based intervention group and − 3.0 (− 7.0–1.0) in the educational lecture group, reflecting a significant reduction of stigma levels in the contact-based intervention group. On examining the SSCP subscales, scores for factor I and factor II significantly improved. The educational program was more effective for pharmacists aged 20–39 years or with negligible experience of communicating with PDS at work and/or in private life. Conclusions: SSCP and the educational program for community pharmacists that focuses on communication with PDS were useful for assessing and reducing, respectively, the stigma attached by these pharmacists to schizophrenia. Trial registration: UMIN Clinical Trials Registry (UMIN000043189, registered on January 30, 2021), Retrospectively registered.

31 May 2018 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
MHMasakazu Hatano
Masakazu Hatano
HKHiroyuki Kamei
Hiroyuki Kamei
RIRisa Inagaki
Risa Inagaki
HMHaruna Matsuzaki
Haruna Matsuzaki
MHManako Hanya
Manako Hanya
NINakao Iwata
Nakao Iwata
Masakazu Hatano, Hiroyuki Kamei, Risa Inagaki, Haruna Matsuzaki, Manako Hanya, Shigeki Yamada, Nakao Iwata. Clin Psychopharmacol Neurosci 2018;16:184-9. https://doi.org/10.9758/cpn.2018.16.2.184

8 April 2017 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
MHManako Hanya
Manako Hanya
YKYoshitake Kanno
Yoshitake Kanno
JAJunko Akasaki
Junko Akasaki
KAKeiko Abe
Keiko Abe
KFKazuhiko Fujisaki
Kazuhiko Fujisaki
HKHiroyuki Kamei
Hiroyuki Kamei
With the development of pharmacotherapy and radiotherapy, cancer treatment is being shifted from surgical to outpatient services, consequently increasing insurance-covered pharmacies’ frequency of dealing with cancer patients. As the psychology of these patients is complex, it is necessary for pharmacists to educate them in consideration of their cognitive/medical and psychosocial aspects. This study analyzed cancer patient management by pharmacists working in such pharmacies and their communication skills before and after communication skill training based on SPIKES, a six-step protocol for delivering bad news, to confirm the usefulness of such training. The study involved 20 pharmacists working in insurance-covered pharmacies within Aichi Prefecture. Before and after communication skill training, role-play sessions were held using standardized patients, whose levels of satisfaction were subsequently measured. Patient management by the pharmacists was analyzed using the Roter Interaction Analysis System as a method to analyze dialogues. The rate of each category, representing the pharmacists’ conversation styles when dealing with the patients, changed after communication skill training as follows: [Giving information]: decreased from 37.0 to 27.6%; [Empathy statements]: increased from 12.0 to 17.2%; and [Data gathering]: increased from 18.0 to 23.3%. The increase was particularly marked in: [Acceptance], accepting patients’ emotions and events in line with [Empathy statements]; [Promoting dialogues] as a sub-category of [Building a relationship]; and [Checks for understanding] as a sub-category of [Data gathering]. Furthermore, the results of pharmacist assessment by the patients, including their levels of overall satisfaction, showed significant correlations with [Empathy statements] and [Building a relationship]. Communication skill training may be effective to improve pharmacists’ conversation styles to listen to patients more attentively, accept their emotions, and provide education in accordance with their needs, rather than unilaterally providing information. The study was approved by the Ethical Review Board of Meijo University as a research activity involving humans (approval number: H26-1 ).

3 November 2022 in Medicina
Verified
Journal Article
Open access
PDF file
HKHiroyuki Kamei
Hiroyuki Kamei
Schizophrenia is a chronic psychiatric disease that is characterized by psychotic symptoms, including positive, negative, affective, and aggressive symptoms, as well as cognitive dysfunction, and is primarily treated using drug therapy, the continuation of which is essential to prevent recurrence/recrudescence. Various second-generation antipsychotics with pharmacological properties or adverse events that differ from those of conventional antipsychotics have recently been introduced, and pharmaceutical management is required for drug efficacy assessments and adverse event monitoring/management of these drugs. Antipsychotic monotherapy (APM) is the gold standard treatment for schizophrenia and is recommended in various guidelines. However, a subgroup of patients with schizophrenia do not or only partially respond to APM. Therefore, antipsychotic polypharmacy (APP), in which ≥2 antipsychotics are combined, has been routinely utilized to compensate for insufficient responses to APM in clinical practice. APP has recently been proposed as an evidence-based treatment option, but does not consider clinicians’ experience. However, the risk of APP-related adverse events is high. The application of APP needs to be carefully reviewed, whilst taking into consideration patient backgrounds. Furthermore, the risk of APP-related adverse events is higher in elderly patients than in the general population; therefore, caution is needed. This review discusses the merits of APP, matters that need to be considered, and a switch from APP to APM, and also focuses on the application of APP in clinical practice.

29 February 2020 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
HKHiroyuki Kamei
Hiroyuki Kamei
YHYuki Homma
Yuki Homma
ITIppei Takeuchi
Ippei Takeuchi
GHGenta Hajitsu
Genta Hajitsu
KTKaori Tozawa
Kaori Tozawa
NINakao Iwata
Nakao Iwata
Hiroyuki Kamei, Yuki Homma, Ippei Takeuchi, Genta Hajitsu, Kaori Tozawa, Masakazu Hatano, Aiko Fukui, Manako Hanya, Shigeki Yamada, Nakao Iwata. Clin Psychopharmacol Neurosci 2020;18:49-57. https://doi.org/10.9758/cpn.2020.18.1.49